# Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

> **NCT03847246** · NA · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Baraclude® tablets,1.0 mg
- **DRUG:** Entecavir tablets,1.0 mg

## Key facts

- **NCT ID:** NCT03847246
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2018-12-28
- **Final completion:** 2018-12-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847246, "Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03847246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*